Plain-English translation of NCT07487727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to treat anemia (low red blood cell counts) caused by chronic kidney disease in people who haven't started dialysis yet. The medication will be compared head-to-head with a standard anemia treatment that doctors already use. Researchers want to see if this new treatment is safe and works better at helping your body make more red blood cells.
People with chronic kidney disease often develop anemia because their kidneys can't produce enough of a hormone that tells the body to make red blood cells. While existing treatments help some patients, doctors are looking for new options that might work even better or have fewer side effects.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or the standard anemia treatment. The study is open-label, which means you and your doctors will know which treatment you're getting. You'll visit the study center multiple times for blood tests to check your hemoglobin levels, kidney function, and overall health, and doctors will monitor you for any side effects throughout the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China